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Our patient, a 32-year-old man, presented to Themba lethu
Clinic with AIDS in November 2004. He had been diagnosed
with HIV infection in 2000. At that time he was asymptomatic
and attended the state HIV clinic.
His first admission was for Pneumocystis jiroveci pneumonia
(PCP). At the time our unit was screening patients for a clinical
trial. This patient was not our ‘usual’ trial candidate. He had
been expelled from school, had drug and alcohol addictions
and a criminal conviction, and was unable to maintain
employment (all indicating antisocial personality traits). He
also had a history of poor compliance to prescribed
medications. Any of these behaviours could have convinced us
that he would be unsuitable for the stringent requirements for
compliance and clinic follow-up required by clinical trials.
In addition his economic vulnerability could have made study
participation complicated. He lives in a shelter for homeless
people living with AIDS. This is a scarce resource in South
Africa, a country where many people survive on an income of
R150/month. This financial reimbursement is the SA Medicines
Control Council (MCC) requirement for study clinic visits. 
Despite these challenges, the clinic staff were convinced that
the patient understood the severity of his disease and that
ongoing support would ensure success.
His past medical history included two episodes of pulmonary
tuberculosis (TB), in 2003 and 2004 . He was poorly compliant
to standard anti-TB drugs (isoniazid (INH), rifampicin (RIF),
pyrazinamide (PZA) and ethambutol) during  both treatment
periods. He also had psoriasis since adolescence.
On initial examination the patient had clinical AIDS, PCP,
severe generalised psoriasis, and extensive mucocutaneous
Kaposi’s sarcoma (KS) lesions. The twice-daily HAART study
regimen (lopinavir/ ritonavir 400/100 mg + stavudine 30 mg +
3TC 150 mg bd) was commenced on 19 November 2004. These
drugs are available from the South African national
antiretroviral (ARV) programme. The pneumonia responded to
co-trimoxazole but the pyrexia and anaemia persisted,
necessitating readmission in December 2004. Sputum
microscopy was now positive for mycobacteria and the
retreatment regimen of RIF, INH, ethambutol, PZA, +
streptomycin was commenced. At this time the CD4 count was
18 cells/µl and the viral load > 100 000 copies/ml. The
lopinavir/ritonavir was replaced by efavirenz because of the
potential interaction with RIF. Ultrasound examination
showed marked hepatosplenomegaly and numerous small
abdominal lymph nodes which were presumed to be
consistent with TB or possibly visceral KS. 
The patient was admitted for a second time in December
because of deterioration in his general condition and also to
assist with compliance with these complicated drug regimens.
In January 2005 he developed abdominal pain, vomiting and
respiratory distress. Immune reconstitution inflammatory
syndrome (IRIS) or a complication of abdominal TB was
considered. Intestinal obstruction was excluded and severe
oesophageal candidiasis was diagnosed on gastroscopy. The
abdominal ultrasound findings remained unchanged.
A Bactec blood culture was positive for Mycobacterium
tuberculosis complex and M. avium complex despite 2 months
of TB directly observed therapy (DOT).  Bone marrow trephine
biopsy on 28 February revealed features consistent with
anaemia of chronic disease and a Ziehl-Neelsen stain was
positive for mycobacteria.
Fluconazole and azithromycin were added to the regimen.
Standard anti-TB drugs were continued while awaiting the
Middlebrook indirect susceptibility results.
In March the antibiogram showed resistance to RIF and partial
INH sensitivity, susceptibility to ethambutol being retained. RIF
and streptomycin were replaced by ciprofloxacin and amikacin
and the patient was transferred to a TB hospital. He did not
co-operate with staff at this hospital and was returned to our
care. A liver aspirate confirmed the presence of  granulo-
matous hepatitis but stains and immunohistochemistry
(CD34) were negative for mycobacteria and KS respectively.
The patient developed bilateral oedema and inflammation of
the lower limbs in hospital, and a deep-vein thrombosis (DVT)
was excluded by Doppler ultrasound.
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He was admitted again in May 2005 with worsening
abdominal pain, vomiting, new cough and fever and painful
feet.
The patient was diagnosed as having KS involvement of the
feet, but peripheral neuropathy induced by stavudine or INH
could not be excluded. Stavudine was replaced with tenofovir
(obtainable by application to the MCC under section 22 on a
named patient basis).
A computed tomography (CT) scan showed KS-associated
hepatosplenomegaly with focal lesions, pulmonary nodules
and a mass in the left ventricle. However, an encouraging sign
was that for the first time since commencing HAART 7 months
previously he achieved a viral load of < 50 copies/ml and a
CD4 count of 179 cells/µl.
In June 2005 he was referred to the oncologists for worsening
KS, probably related to IRIS. A skin biopsy confirmed plaque-
phase KS, but interestingly stains for HHV8 were negative.
In July the patient arrived at the outpatient clinic with a new
episode of fever, insomnia and tiredness. The pharmacy had
not been dispensing amikacin, azithromycin and ciprofloxacin.
On their reintroduction the symptoms abated. On 27 July he
received the first dose of chemotherapy (adriamycin,
etopicide) for KS. Surprisingly he tolerated the drugs well and
experienced only tiredness, hair loss and anaemia.
We believe that our team’s constant vigilance and persistence
for 10 months have extended this patient’s life. Integral to his
care has been regular telephonic and clinic follow-up. Our
greatest challenge was ensuring that he obtained the
prescribed drugs. To our surprise he was compliant on the 13
different oral medications and 1 intramuscular injection daily
for 8 months. One can only imagine the discipline and
commitment  required. Drug adverse effects and interactions
would have overwhelmed anyone with a weaker resolve. He
has had 7 admissions and required frequent social, laboratory
and radiological monitoring (3 tissue biopsies, 1 CT scan, 3
ultrasound scans, 6 chest X-rays). 
Every small improvement in the patient’s health gives him a
sense of achievement. He has been reunited with his family
and has dealt with his feelings of guilt for the suffering he
caused them. He acknowledges a second chance at life,
recognises his own self-worth and looks forward to a better
quality of life. He is now concerned about his future.  He faces
a number of challenges, as his current shelter is intended for
terminal AIDS patients. As he recovers he will have to seek
employment in an environment where jobs for unskilled
people are scarce.  He may no longer qualify for the state
disability grant and will have to obtain independent
accommodation. Re-entering a social environment in which
crime and drug abuse are constant temptations will also be
challenging.
The health care team continues to benefit from this
experience. Everyday we are faced with AIDS victims who do
not have access to ARVs or present too late. The South African
ARV programme is in a fledgeling phase where misinformation
and stigma regarding AIDS and ARVs still abound. Staff are
despondent over overwhelming patient numbers, poor clinical
facilities and support. 
This case provides proof, and extends our hope, that  even in
late-stage AIDS and with numerous medical and social
problems, and even within a resource-limited public health
system, patients can still benefit from our interventions.
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The recent highly successful launch of the KOSH  Branch 
(Klerksdorp/Orkney/Stilfontein and Haartebeesfontein) 
THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE                                            MARCH 2006
